We are live on
!
Find out more
First Trust Advisors Portfolio holdings
AUM
$140B
1-Year Est. Return
27.84%
This Fund
S&P 500
This Quarter
Est. Return
+1.3%
1 Year Est. Return
+27.84%
3 Year Est. Return
+78.79%
5 Year Est. Return
+98.89%
10 Year Est. Return
+456.9%
AUM
$38.5B
AUM Growth
+$4.48B
(+13%)
Cap. Flow
+$4.55B
Cap. Flow
% of AUM
11.82%
Top 10 Holdings %
Top 10 Hldgs %
13.89%
Holding
2,364
New
149
Increased
1,180
Reduced
895
Closed
134
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
First Trust NYSE Arca Biotechnology Index Fund
FBT
|
+$275M |
| 2 |
First Trust Health Care AlphaDEX Fund
FXH
|
+$221M |
| 3 |
First Trust Dow Jones Internet Index Fund ETF
FDN
|
+$193M |
| 4 |
First Trust Consumer Staples AlphaDEX Fund
FXG
|
+$188M |
| 5 |
First Trust Consumer Discretionary AlphaDEX Fund
FXD
|
+$179M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$230M |
| 2 |
Spectrum Brands
SPB
|
+$81.6M |
| 3 |
Chevron
CVX
|
+$79.8M |
| 4 |
Pfizer
PFE
|
+$66.7M |
| 5 |
K
Kellanova
K
|
+$63.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.09% |
| 2 | Consumer Discretionary | 10.38% |
| 3 | Technology | 9.81% |
| 4 | Consumer Staples | 7.93% |
| 5 | Communication Services | 6.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Akamai
AKAM
$16.9B
| $127M | 0.33% |
1,813,248
+279,647
| +18% | +$20.8M |
|
52
Pilgrim's Pride
PPC
$6.78B
| $126M | 0.33% |
5,482,262
+2,310,107
| +73% | +$57.2M |
|
53
Vertex Pharmaceuticals
VRTX
$121B
| $124M | 0.32% |
1,001,124
+150,498
| +18% | +$19M |
|
54
AT&T
T
$163B
| $123M | 0.32% |
4,591,412
-1,408,834
| -23% | -$36.4M |
|
55
Archer Daniels Midland
ADM
$41.6B
| $123M | 0.32% |
2,551,639
+492,431
| +24% | +$24.8M |
|
56
Cisco
CSCO
$449B
| $123M | 0.32% |
4,478,378
+528,019
| +13% | +$15.1M |
|
57
Nektar Therapeutics
NKTR
$2.4B
| $122M | 0.32% |
648,423
+228,082
| +54% | +$39.3M |
|
58
Centene
CNC
$31.2B
| $120M | 0.31% |
2,986,184
-67,322
| -2% | -$2.42M |
|
59
Agios Pharmaceuticals
AGIO
$2.16B
| $120M | 0.31% |
+1,079,286
| New | +$116M |
|
60
Monster Beverage
MNST
$91.6B
| $119M | 0.31% |
5,335,950
-1,822,950
| -25% | -$40.7M |
|
61
Alkermes
ALKS
$8.81B
| $119M | 0.31% |
1,851,233
-268,527
| -13% | -$16.4M |
|
|
RAD
62
DELISTED
Rite Aid Corporation
RAD
| $118M | 0.31% |
708,416
-15,522
| -2% | -$2.61M |
|
|
ICPT
63
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $118M | 0.31% |
487,459
-150,815
| -24% | -$40.2M |
|
|
CTRX
64
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| $117M | 0.3% |
1,908,748
+171,735
| +10% | +$10.3M |
|
65
McKesson
MCK
$97.8B
| $115M | 0.3% |
513,523
+96,087
| +23% | +$22.2M |
|
|
AGN
66
DELISTED
Allergan plc
AGN
| $115M | 0.3% |
379,818
-9,252
| -2% | -$2.76M |
|
|
QGENF
67
DELISTED
QIAGEN NV
QGENF
| $115M | 0.3% |
4,620,861
-42,007
| -0.9% | -$1.04M |
|
68
Cencora
COR
$60B
| $114M | 0.3% |
1,072,711
+27,543
| +3% | +$3.1M |
|
|
MNK
69
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $114M | 0.3% |
967,863
+211,998
| +28% | +$26.1M |
|
70
Equinix
EQIX
$108B
| $114M | 0.29% |
447,282
+56,761
| +15% | +$14.5M |
|
|
PDLI
71
DELISTED
PDL BioPharma, Inc.
PDLI
| $113M | 0.29% |
17,536,793
+3,424,045
| +24% | +$22.9M |
|
72
HCA Healthcare
HCA
$84.2B
| $113M | 0.29% |
1,241,512
-1,845
| -0.1% | -$148K |
|
73
Procter & Gamble
PG
$342B
| $111M | 0.29% |
1,423,714
+1,127,697
| +381% | +$90.7M |
|
74
Expedia Group
EXPE
$31.6B
| $111M | 0.29% |
1,018,105
+176,220
| +21% | +$18.2M |
|
|
LNKD
75
DELISTED
LinkedIn Corporation
LNKD
| $110M | 0.29% |
534,343
+120,711
| +29% | +$26.9M |
|
Similar funds
DAM
First Trust Advisors's Q2 2015 Portfolio in Review
As of Q2 2015, First Trust Advisors held 2,364 positions worth $38.5B, up 13% from $34B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
First Trust Advisors deployed $4.55B of net new capital in Q2 2015, opening 149 new positions and adding to 1,180 existing holdings. Its largest new stake was Agios Pharmaceuticals: 1,079,286 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Chevron, an estimated $79.8M trimmed.
- First Trust Advisors's largest Q2 2015 buy was Agios Pharmaceuticals: 1,079,286 shares worth $120M.
- First Trust Advisors added most to First Trust NYSE Arca Biotechnology Index Fund in Q2 2015, an estimated $275M increase.
- First Trust Advisors's biggest Q2 2015 reduction was Chevron, cutting an estimated $79.8M.
- First Trust Advisors fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $230M.
- First Trust Advisors's ten largest holdings make up 14% of its $38.5B portfolio in Q2 2015.
- First Trust Advisors opened 149 new positions and closed 134 in Q2 2015.
- First Trust Advisors's portfolio value rose 13% quarter-over-quarter to $38.5B.
Based on First Trust Advisors's 13F filing for Q2 2015, filed 4 Aug 2015.